

local prices in the market as well as the prices fixed by Government;

(b) what are the imported raw materials required for the production of each item per Kg. with details of each raw material with CIF price and the outgo of foreign exchange in each item per Kg.;

(c) what is the present production of these 12 drugs by foreign companies in the country; and

(d) whether it is a fact that according to the New Drug Policy announced in 1978 the foreign companies were required to produce these items from basic stages within a period of two years?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VASANT SATHE): (a) to (c) The requisite data, to the extent available is given in the attached Statement. [See Appendix CXXXVI, Annexure No. 70]

(d) As per drug policy foreign companies producing bulk drugs from penultimate stage will have to manufacture, within a period of 2 years the bulk drugs concerned from the basic stage. Out of the list of drugs referred to, only Halothane is made from penultimate stage.

**Manufacture of Sulphamethoxazole .  
by M/s Roche\***

1401. SHRI MIRZA IRSHADBAIG AIYUBBAIG: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to refer to the answer to Unstarred Question 496 given in the Rajya Sabha on the 14th March, 1983 and state:

(a) whether it is a fact that 12 criteria laid down by the Committee on High Technology are of general nature and manufacturing processes of most of the bulk drugs conform to one or more of these criteria;

(b) whether Government's attention has been drawn to a number of reports and articles published recently stating that the criteria are so general in nature that no assessment of technology can be made on the basis of these criteria;

(c) if so, what is Government's reaction thereto;

(d) how subsequent to the submission of report, process of manufacture of Sulphamethoxazole by M/s. Roche has been identified as involving high technology; and

(e) what is the share of Roche in the total production of Sulphamethoxazole in the country?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VASANT SATHE): (a) to (c) While categorising the process as high or low, the High Level Committee have taken into consideration various process details with reference to the 12 main parameters adopted by them. These parameters have been recently referred to in the 'Times of India' news item dated 6th April, 1983. A majority of the bulk drugs considered by the committee were categorised as low technology ones.

(d) Sulphamethoxazole which was being produced by M/s. Roche Products from an intermediate stage, was categorised as not involving "high" technology by the High Level Committee on the basis of data submitted by the company because the processes from the intermediate stage did not satisfy the criteria laid down by the said Committee. Subsequently M/s. Roche Products have started manu-

ufacture of this drug from basic stages and the process involved from basic stages satisfies more than one criteria laid down by the High Level Committee. Hence this drug is at present

being treated as involving "high" technology.

(e) Requisite information is given below:—

(Figures in Tonnes)

Year	Total Production in organised sector	Production of M/s. Roche
1981-82 . . . . .	157.00	34.31
1982-83 (April-Dec., 82) . . . . .	130.89	13.11

Apart from the above, production of Sulphamethoxazole in the small scale sector, as per data available is as under:—

1981-82 . . . . .	76.23 Tonnes
(1982-83 . . . . . April-Dec. 82)	57.85 Tonnes

#### Production of Cyproheptadine by M/s. Merck Sharp and Dhome

1402. SHRI MIRZA IRSHADBAIG AIYUBBAIG: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to refer to the answer to Unstarred Question 1527 given in tb\* Rajya Sabha on the 14th March, 1983 and state:

(a) whether M/s. Merck Sharp and Dhome have submitted their manufacturing processes for the production of Cyproheptadine to the High Level Committee, if so, what was the stage of manufacture shown in the process examined by the Committee;

(b) whether it was known to the Committee that this company does not have Industrial Licence to manufacture Cyproheptadine from Cypro-carbinol base and the foreign exchange spent on Cyprocarbinol base is much more than the price of the bulk drug then how the company was allowed to manufacture Cyproheptadine from imported Cyprocarbinol base even after the New Drug Policy; and

(c) whether any comparison of the price of Cyproheptadine and Cy-procarbino base was made to establish the extent of over invoicing involved in the transaction of import of Cyprocarbino base?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VASANT SATHE): (a) M/s. Merck Sharp & Dohme had indicated to the High Level Committee that they were producing Cyproheptadine HCL from the penultimate stage. The High Level Committee categorised the technology of this drug as 'Not high'.

(b) The company was producing this drug under explanation 2 to Schedule I of KD&R) Act, 1951. Its Industrial Licence application for manufacture of this drug has been rejected and the company asked to stop its production.

(c) The price of imported Cyproheptadine HCL in 1980-81 was Rs. 2 per gram C.I.F. The import content per gram of production by Merck Sharp & Dohme on import of Cyprocarbino base was indicated by the BICP as Rs. 9.989 CIF in their report submitted to the Government in 1979.

#### IDPL unit at Sangrur, Punjab

1403. SHRI RAMCHANDRA BHARADWAJ: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state;